<DOC>
	<DOCNO>NCT02031133</DOCNO>
	<brief_summary>Study SPC3649-207E design extension study prior protocol provide additional long-term safety efficacy information subject participate Study SPC3649-207 .</brief_summary>
	<brief_title>Long-term Extension Miravirsen Study Null Responder Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participated study SPC3649207 Received investigational drug therapy discontinuation , termination , successful completion study SPC3649207</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Antisense</keyword>
	<keyword>miR-122 antagonist</keyword>
	<keyword>host factor</keyword>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>